As global markets experience broad-based gains, with smaller-cap indexes outperforming large-caps and the S&P MidCap 400 Index showing significant growth, investors are closely watching economic indicators such as initial jobless claims and existing home sales that have driven positive sentiment. In this environment of cautious optimism, a good high-growth tech stock is often characterized by its ability to innovate and adapt to market demands while maintaining solid financial health amidst evolving economic conditions.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Material Group |
20.45% |
24.01% |
★★★★★★ |
|
Yggdrazil Group |
24.66% |
85.53% |
★★★★★★ |
|
Sarepta Therapeutics |
24.00% |
42.49% |
★★★★★★ |
|
Mental Health TechnologiesLtd |
24.68% |
97.53% |
★★★★★★ |
|
Medley |
25.57% |
31.67% |
★★★★★★ |
|
TG Therapeutics |
34.66% |
56.98% |
★★★★★★ |
|
Alkami Technology |
21.89% |
98.60% |
★★★★★★ |
|
Alnylam Pharmaceuticals |
22.44% |
70.66% |
★★★★★★ |
|
Travere Therapeutics |
31.70% |
72.51% |
★★★★★★ |
|
JNTC |
29.48% |
104.37% |
★★★★★★ |
Click here to see the full list of 1288 stocks from our High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Vitrolife AB (publ) specializes in providing assisted reproduction products and has a market capitalization of SEK30.60 billion.
Operations: Vitrolife AB’s revenue streams are derived from three main segments: Genetics (SEK1.23 billion), Consumables (SEK1.61 billion), and Technologies (SEK721 million). The company focuses on the assisted reproduction market, leveraging these segments to support its operations and growth strategy.
Vitrolife, a company navigating the complex biotech landscape, has shown resilience with an 8.2% annual revenue growth projection, outpacing Sweden’s market average significantly. Despite current unprofitability, its trajectory towards profitability within three years is bolstered by an anticipated earnings growth of 96.77% per year. Recent activities including presentations at prominent healthcare conferences underscore its active engagement with the investment community and commitment to growth amidst challenging market conditions. These developments highlight Vitrolife’s potential in transforming its financial health and industry standing through strategic R&D investments and market engagement.
-
Click to explore a detailed breakdown of our findings in Vitrolife’s health report.
-
Examine Vitrolife’s past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★☆☆
